DCLRE1A — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL10397478	0.72	1/20
SCHEMBL11296003	0.70	1/20
SCHEMBL7019419	0.66	1/20
SCHEMBL13681701	0.66	1/20
Hydrochloric Acid (SCHEMBL5704000)	0.62	1/20
SCHEMBL26679439	0.62	1/20
SCHEMBL68982	0.61	1/20
Benzene (SCHEMBL1931924)	0.61	1/20
SCHEMBL2356669	0.61	1/20
SCHEMBL30616786	0.61	1/20
SCHEMBL2789149	0.61	1/20
SCHEMBL2770912	0.59	1/20
Hydrochloric Acid (SCHEMBL11162468)	0.59	1/20
Water (SCHEMBL29008379)	0.59	1/20
Methane (SCHEMBL29008389)	0.59	1/20
SCHEMBL29008375	0.59	1/20
SCHEMBL2462821	0.58	1/20
SCHEMBL2536183	0.58	1/20
SCHEMBL28279304	0.58	1/20
Formaldehyde (SCHEMBL29008382)	0.58	1/20

Clinical trials — most relevant to DCLRE1A by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency	PHASE2/PHASE3	RECRUITING
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma	PHASE1/PHASE2	COMPLETED
Chlorambucil in Metastatic PDAC Patients Bearing a Germ Line DNA Defects Repair Mutations (SALE Trial)	PHASE2	UNKNOWN
Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and AMD3100	PHASE1/PHASE2	COMPLETED
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation	PHASE2	UNKNOWN
Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation	PHASE2	UNKNOWN
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
Phase II ABT-888 With Cyclophosphamide	PHASE2	COMPLETED
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies	PHASE1/PHASE2	RECRUITING
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers	PHASE1	COMPLETED
AZD1775 for Advanced Solid Tumors	PHASE1	COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas	PHASE1	COMPLETED
Clinical Genetics Branch Eligibility Screening Survey	nan	NOT_YET_RECRUITING
Study of the Effect of Innate on the Inflammatory Response to Endotoxin	nan	RECRUITING
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients	nan	COMPLETED
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients	nan	ACTIVE_NOT_RECRUITING
DNA Repair Genes and Outcomes in Patients With Stage III NSCLC	nan	UNKNOWN
DNA Damage & Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease	nan	COMPLETED
Study of Markers of Cosmic Radiation Exposure and Effect Among Flight Crews	nan	COMPLETED
Telomere Repair Gene Mutation in Inflammatory Bowel Disease	nan	COMPLETED
Prognostic Biomarkers in Patients With Urothelial Carcinoma	nan	COMPLETED
Molecular Genetic Studies of Childhood Brain Tumors and Blood Samples	nan	COMPLETED
Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer, Localized Prostate Cancer, or Gynecological Cancer	nan	UNKNOWN
Studying Tissue Samples From Patients With Stage II Colon Cancer Treated on Clinical Trial CLB-9581	nan	COMPLETED
Application of Genetic Polymorphisms of DNA Repair in The Prediction of Prostate Cancer Susceptibility and Its Clinical Outcome	nan	UNKNOWN
Immunogenetics of Visceral Leishmaniasis	nan	COMPLETED
Pharmacogenomic Association Study in Indian Children With Acute Lymphoblastic Leukemia	nan	RECRUITING
The Genetic and the Functional Study of DNA Repair System and the Susceptibility to Rheumatoid Arthritis	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a DCLRE1A binder may also engage these)

Protein	Name	Similarity
Q9JIC3	—	1.000	Q9JIC3 →
Q5QJC4	—	1.000	Q5QJC4 →
A0JM80	—	0.994	A0JM80 →
Q5W0B1	—	0.993	Q5W0B1 →
Q5ZLE9	—	0.993	Q5ZLE9 →
Q9Z1J2	—	0.993	Q9Z1J2 →
Q6NRK3	—	0.992	Q6NRK3 →
Q9UHC1	—	0.992	Q9UHC1 →
Q9Z2U2	—	0.992	Q9Z2U2 →
Q3U285	—	0.992	Q3U285 →
Q6A037	—	0.992	Q6A037 →
Q56NI9	—	0.992	Q56NI9 →
E7FAP1	—	0.992	E7FAP1 →
Q6KAQ7	—	0.992	Q6KAQ7 →
P10244	—	0.992	P10244 →
Q9NYI0	—	0.992	Q9NYI0 →
Q6GNV6	—	0.992	Q6GNV6 →
Q4G163	—	0.991	Q4G163 →
O88700	—	0.991	O88700 →
Q5TKR9	—	0.991	Q5TKR9 →
A0JNH9	—	0.991	A0JNH9 →
O75113	—	0.991	O75113 →
Q6NWW5	—	0.991	Q6NWW5 →
Q9JKY3	—	0.991	Q9JKY3 →
Q8IYW4	—	0.991	Q8IYW4 →
F1M5M3	—	0.991	F1M5M3 →
Q66H04	—	0.990	Q66H04 →
Q5DW34	—	0.990	Q5DW34 →
Q6DFV7	—	0.990	Q6DFV7 →
Q9ULD2	—	0.990	Q9ULD2 →